Vitamin D and DDX4 regulate the proliferation and invasion of ovarian cancer cells

Chen,Youguo; Sun,Ziqian; Xu,Jingbo; Wang,Peifang; Tang,Juan; Shi,Xiaorui; Liu,Jingjing; Ren,Fangfang; Xu,Lan

doi:10.3892/ol.2018.8718

Vitamin D and DDX4 regulate the proliferation and invasion of ovarian cancer cells

Authors:
- Youguo Chen
- Ziqian Sun
- Jingbo Xu
- Peifang Wang
- Juan Tang
- Xiaorui Shi
- Jingjing Liu
- Fangfang Ren
- Lan Xu
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology, Soochow University Medical College, Suzhou, Jiangsu 215123, P.R. China, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215123, P.R. China
Published online on: May 16, 2018 https://doi.org/10.3892/ol.2018.8718
Pages: 905-909
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is one of the most commonly occurring types of cancer and one of the most common causes of cancer‑associated mortality in women. Diagnosis of ovarian cancer at an early stage is difficult due to the lack of specific symptoms. In the present study, it is demonstrated that active vitamin D treatment prohibited the proliferation and invasion of ovarian cancer cells, and the expression level of a germ cell specific marker DEAD (Asp‑Glu‑Ala‑Asp)‑box helicase 4 (DDX4), which is overexpressed in ovarian cancer, was downregulated by active vitamin D treatment. Knockdown of DDX4 by siRNA could also suppress the invasive ability of ovarian cancer cells. Therefore, DDX4 may be considered as a diagnostic marker of ovarian cancer, and vitamin D may be a candidate drug for ovarian cancer therapy.

View Figures

View References

1	Lim HJ and Ledger W: Targeted therapy in ovarian cancer. Womens Health (Lond). 12:363–378. 2016.PubMed/NCBI
2	Clarke-Pearson DL: Clinical practice. Screening for ovarian cancer. N Engl J Med. 361:170–177. 2009. View Article : Google Scholar : PubMed/NCBI
3	Jelovac D and Armstrong DK: Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 61:183–203. 2011. View Article : Google Scholar : PubMed/NCBI
4	Guenther J, Stiles A and Champion JD: The lived experience of ovarian cancer: A phenomenological approach. J Am Acad Nurse Pract. 24:595–603. 2012. View Article : Google Scholar : PubMed/NCBI
5	Yahara K, Ohguri T, Imada H, Yamaguchi S, Kawagoe T, Matsuura Y, Hachisuga T and Korogi Y: Epithelial ovarian cancer: Definitive radiotherapy for limited recurrence after complete remission had been achieved with aggressive front-line therapy. J Radiat Res. 54:322–329. 2013. View Article : Google Scholar : PubMed/NCBI
6	Baruah U, Barmon D, Kataki AC, Deka P, Hazarika M and Saikia BJ: Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study. Indian J Med Paediatr Oncol. 36:38–42. 2015. View Article : Google Scholar : PubMed/NCBI
7	Wahler J, So JY, Cheng LC, Maehr H, Uskokovic M and Suh N: Vitamin D compounds reduce mammosphere formation and decrease expression of putative stem cell markers in breast cancer. J Steroid Biochem Mol Biol. 148:148–155. 2015. View Article : Google Scholar : PubMed/NCBI
8	So JY and Suh N: Targeting cancer stem cells in solid tumors by vitamin D. J Steroid Biochem Mol Biol. 148:79–85. 2015. View Article : Google Scholar : PubMed/NCBI
9	Garland CF, Mohr SB, Gorham ED, Grant WB and Garland FC: Role of ultraviolet B irradiance and vitamin D in prevention of ovarian cancer. Am J Prev Med. 31:512–514. 2006. View Article : Google Scholar : PubMed/NCBI
10	Granato T, Manganaro L, Petri L, Porpora MG, Viggiani V, Angeloni A and Anastasi E: Low 25-OH vitamin D levels at time of diagnosis and recurrence of ovarian cancer. Tumour Biol. 37:2177–2181. 2016. View Article : Google Scholar : PubMed/NCBI
11	Castrillon DH, Quade BJ, Wang TY, Quigley C and Crum CP: The human VASA gene is specifically expressed in the germ cell lineage. Proc Natl Acad Sci USA. 97:9585–9590. 2000. View Article : Google Scholar : PubMed/NCBI
12	Hashimoto H, Sudo T, Mikami Y, Otani M, Takano M, Tsuda H, Itamochi H, Katabuchi H, Ito M and Nishimura R: Germ cell specific protein VASA is over-expressed in epithelial ovarian cancer and disrupts DNA damage-induced G2 checkpoint. Gynecol Oncol. 111:312–319. 2008. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Kim KH, Kang YJ, Jo JO, Ock MS, Moon SH, Suh DS, Yoon MS, Park ES, Jeong N, Eo WK, et al: DDX4 (DEAD box polypeptide 4) colocalizes with cancer stem cell marker CD133 in ovarian cancers. Biochem Biophys Res Commun. 447:315–322. 2014. View Article : Google Scholar : PubMed/NCBI
15	Tavani A, Bertuccio P, Bosetti C, Talamini R, Negri E, Franceschi S, Montella M and La Vecchia C: Dietary intake of calcium, vitamin D, phosphorus and the risk of prostate cancer. Eur Urol. 48:27–33. 2005. View Article : Google Scholar : PubMed/NCBI
16	Wang WL, Welsh J and Tenniswood M: 1,25-Dihydroxyvitamin D3 modulates lipid metabolism in prostate cancer cells through miRNA mediated regulation of PPARA. J Steroid Biochem Mol Biol. 136:247–251. 2013. View Article : Google Scholar : PubMed/NCBI
17	Wang WL, Chatterjee N, Chittur SV, Welsh J and Tenniswood MP: Effects of 1α,25dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 10:582011. View Article : Google Scholar : PubMed/NCBI
18	Thorne J and Campbell MJ: The vitamin D receptor in cancer. Proc Nutr Soc. 67:115–127. 2008. View Article : Google Scholar : PubMed/NCBI
19	Giovannucci E: Expanding roles of vitamin D. J Clin Endocrinol Metab. 94:418–420. 2009. View Article : Google Scholar : PubMed/NCBI